Sector News

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

September 15, 2020
Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the U.K.

Announced over the weekend, the U.K. Big Pharma said its vaccine, known as AZD1222, “has resumed in the U.K. following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.”

It was halted at the start of last week over a serious safety concern. AstraZeneca was, and still is, keeping mum on the exact nature of what happened, but according to a New York Times report that cited a person familiar with the situation, a participant based in the U.K. was found to have transverse myelitis, an inflammatory syndrome that affects the spinal cord and is often sparked by viral infections.

In its statement over the weekend, AZ said it “cannot disclose further medical information” about why it halted, but added, “All trial investigators and participants will be updated with the relevant information and this will be disclosed on global clinical registries, according to the clinical trial and regulatory standards.”

The World Health Organization has cited AZD1222, a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus that contains the genetic material of the SARS-CoV-2 virus spike protein, as a leading contender in the race for a vaccine.

Around 18,000 participants have had AZD1222 as part of the trial, AZ said.

While AZ and Oxford have been highlighted as race leaders, so too have Pfizer and BioNTech, which said they now want to boost their phase 2/3 trial for one of their five mRNA vaccines, BNT162b2, from around 30,000 to 44,000.

Also over the weekend, the companies said they have asked the FDA for the extra participants in order to include a broader patient population and with plans to include adolescents as young as 16 and people with chronic, stable HIV (human immunodeficiency viruses), hepatitis C or hepatitis B infection to “provide additional safety and efficacy data.”

It said it’s on track to hit its original target of 30,000 patients this week; despite wanting more people, Pfizer said in a statement that it was still on course to deliver data by the end of next month.

By: Ben Adams

Source: Fierce Biotech

comments closed

Related News

March 15, 2024

Novo’s obesity superstar Wegovy wins FDA nod to cut cardio risks in key label expansion

Life sciences

Novo Nordisk’s fast-growing weight loss med Wegovy just added a new cardiovascular FDA approval to its label, likely enabling the med’s superstar status to reach new levels. The med is now the first weight loss treatment to score an FDA nod to reduce the risk of cardiovascular death, heart attack and stroke in adult patients with cardiovascular disease who have obesity or are overweight.

March 15, 2024

Galderma sets price range for supersized $2.6bn IPO in Europe

Life sciences

Galderma has announced a price range of CHF 49 to CHF 53 ($55.8 to $60.3) per share for floatation on the SIX Swiss Exchange. The Swiss skincare company, which revealed its intention to conduct an initial public offering (IPO) earlier in March, will have 40,453,467 new shares available. The offering also consists of 276,909 existing shares.

March 15, 2024

After transformation under new CEO, Leo Pharma touts innovation model and financial progress

Life sciences

Taking over as CEO for an aging company in dire financial straits and in need of a slim-down was a challenging assignment for Christophe Bourdon. But under Bourdon’s watch, Leo Pharma is taking steps toward a rebound. Last month, the 115-year-old Danish private company reported that it cut its operating costs by 14% in 2023 while increasing its revenues by 7%.

How can we help you?

We're easy to reach